Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
0.5555
Open
0.5372
VWAP
0.54
Vol
491.97K
Mkt Cap
80.50M
Low
0.526
Amount
265.81K
EV/EBITDA(TTM)
--
Total Shares
146.38M
EV
50.08M
EV/OCF(TTM)
--
P/S(TTM)
--
Veru Inc. is a biopharmaceutical company. The Company is focused on developing medicines for the for the treatment of hospitalized COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS) and other viral-related ARDS and for the management of breast and prostate cancers. The Company offers two FDA approved products within its sexual health program, including ENTADFI (tadalafil 5mg and finasteride 5mg capsule), for the treatment of benign prostatic hyperplasia and FC2 Female Condom (internal condom) (FC2), for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. Its breast cancer drug pipeline has four clinical development programs for two drugs, such as enobosarm, an oral selective androgen receptor targeting agonist, and sabizabulin, an oral cytoskeleton disruptor. Its prostate cancer drug pipeline includes sabizabulin, VERU-100 and zuclomiphene citrate.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
0.00
-100%
--
--
0.00
-100%
--
--
0.00
-100%
--
--
Estimates Revision
The market is revising No Change the revenue expectations for Veru Inc. (VERU) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -5.89%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Down
-5.89%
In Past 3 Month
2 Analyst Rating
723.72% Upside
Wall Street analysts forecast VERU stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VERU is 4.50 USD with a low forecast of 4.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
723.72% Upside
Current: 0.546
Low
4.00
Averages
4.50
High
5.00
723.72% Upside
Current: 0.546
Low
4.00
Averages
4.50
High
5.00
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$3
2025-01-02
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$3
2025-01-02
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$3
2024-12-20
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$3
2024-12-20
Reiterates
Strong Buy
Reason
Oppenheimer
Leland Gershell
Buy
Reiterates
$5
2024-11-05
Reason
Oppenheimer
Leland Gershell
Price Target
$5
2024-11-05
Reiterates
Buy
Reason
Oppenheimer notes that Veru presented a meta-analysis of results from four prior placebo-controlled Phase 2 and 3 clinical studies of enobosarm at the ObesityWeek meeting. The firm, which remains positive on the opportunity for enobosarm to pair with GLP-1-based therapy to yield higher-quality and more weight loss, would be buyers ahead of January's top line readout from the Phase 2b QUALITY trial, says the analyst, who keeps an Outperform rating and $5 price target on Veru shares.
B. Riley Securities
William Woods
Strong Buy
Initiates
$5
2024-05-14
Reason
B. Riley Securities
William Woods
Price Target
$5
2024-05-14
Initiates
Strong Buy
Reason
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$3
2024-05-13
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$3
2024-05-13
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Yi Chen
Strong Buy
Maintains
$2 → $3
2024-05-06
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$2 → $3
2024-05-06
Maintains
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Veru Inc (VERU.O) is -2.21, compared to its 5-year average forward P/E of -7.31. For a more detailed relative valuation and DCF analysis to assess Veru Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-7.31
Current PE
-2.21
Overvalued PE
19.42
Undervalued PE
-34.04
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
11.01
Current PS
0.00
Overvalued PS
21.47
Undervalued PS
0.55
Financials
Annual
Quarterly
FY2025Q1
N/A
Total Revenue
FY2025Q1
YoY :
+31.69%
-10.94M
Operating Profit
FY2025Q1
YoY :
-76.39%
-1.81M
Net Income after Tax
FY2025Q1
YoY :
-25.00%
-0.06
EPS - Diluted
FY2025Q1
YoY :
+88.26%
-11.33M
Free Cash Flow
FY2025Q1
N/A
Gross Profit Margin - %
FY2025Q1
N/A
FCF Margin - %
FY2025Q1
N/A
Net Margin - %
FY2025Q1
N/A
ROIC
Trading Trends
Insider
Insiders areBuying! The selling amount has increased 288.8% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
334.4K
USD
6
Bought
0-3
0
0.0
USD
Months
3-6
2
84.3K
USD
Months
6-9
0
0.0
USD
Months
0-12
3
21.7K
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
800.0K
Volume
1
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areBuying! The selling amount has increased 288.8% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
334.4K
USD
6
Bought
0-3
0
0.0
USD
Months
3-6
2
84.3K
USD
Months
6-9
0
0.0
USD
Months
0-12
3
21.7K
USD
Months
VERU News & Events
Events Timeline
2025-02-13 (ET)
2025-02-13
05:40:57
Veru reports Q1 cont-op EPS (1c) vs. (8c) last year
2025-01-27 (ET)
2025-01-27
05:40:57
Veru's enobosarm meets primary endpoint in Phase 2b weight reduction trial
2024-12-31 (ET)
2024-12-31
07:33:22
Veru sells FC2 Female Condom business for $18M
Sign Up For More Events
Sign Up For More Events
News
1.0
04-16NewsfilterVeru to Present at the 2nd Annual GLP-1-Based Therapeutics Summit
9.0
03-08SeekingAlphaWeight-loss drug battle: Who are the latest players involved
9.5
02-13NewsfilterVeru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress
Sign Up For More News
People Also Watch
NNOX
Nano-X Imaging Ltd
4.960
USD
-0.60%
BCAL
Southern California Bancorp
14.120
USD
+0.36%
STOK
Stoke Therapeutics Inc
9.600
USD
+0.95%
LAAC
Lithium Americas (Argentina) Corp
2.740
USD
0.00%
FMNB
Farmers National Banc Corp
13.100
USD
-0.91%
EVLV
Evolv Technologies Holdings Inc
4.255
USD
+3.78%
MGTX
MeiraGTx Holdings PLC
6.920
USD
+0.29%
FFIC
Flushing Financial Corp
12.070
USD
-3.05%
AIRJ
Montana Technologies Corp
4.935
USD
-2.66%
ALT
Altimmune Inc
5.185
USD
+1.67%
FAQ
What is Veru Inc (VERU) stock price today?
The current price of VERU is 0.5463 USD — it has decreased -0.73 % in the last trading day.
What is Veru Inc (VERU)'s business?
What is the price predicton of VERU Stock?
What is Veru Inc (VERU)'s revenue for the last quarter?
What is Veru Inc (VERU)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Veru Inc (VERU)'s fundamentals?
How many employees does Veru Inc (VERU). have?